Document is current
Any future updates will be listed below
-
Authors
Launay, Agathe
Carvalho, Kevin
Genin, Athénais
Gauvrit, Thibaut
Nobili, Paola
Gomez-Murcia, Victoria
Augustin, Emma
Burgard, Anaëlle
Gambi, Johanne
Fourmy, Déborah
Thiroux, Bryan
Vieau, Didier
Bemelmans, Alexis-Pierre https://orcid.org/0000-0001-7605-5225
Le Gras, Stephanie https://orcid.org/0000-0001-6293-6507
Buée, Luc https://orcid.org/0000-0002-6261-4230
Orr, Miranda E.
Audinat, Etienne https://orcid.org/0000-0002-6389-422X
Boutillier, Anne-Laurence https://orcid.org/0000-0002-2317-9280
Bonvento, Gilles https://orcid.org/0000-0002-2886-4228
Cambon, Karine
Faivre, Emilie
Blum, David https://orcid.org/0000-0001-5691-431X
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche
Fondation pour la Recherche Médicale
- License Information
-
More Information
Article History
Received: 23 July 2024
Revised: 13 June 2025
Accepted: 8 July 2025
First Online: 23 July 2025
Competing interests
: DB is a (non-appointed) member of the scientific advisory board of Marvel Biosciences Corp developing an A2AR antagonist. But there is no conflict of interest regarding the present work. Other authors have no competing financial interests in relation to the work described.
